At the beginning of April, many European nations halted their vaccination programme in fears that the Oxford-AstraZeneca Covid-19 vaccine increased the recipient’s chances of developing severe and deadly blood clots.…
First in a series of articles considering the implications of NICE’s changing role for industry and patients. NICE’s role and remit has grown and morphed over its twenty plus year…
As any experienced market access professional will tell you, securing access to a new medicine is rarely as simple as just submitting a dossier to a national body and waiting…
Today sees the launch of Newmarket Strategy, a strategic and technical advisory business specialising in healthcare and life sciences. This new venture brings together three existing companies whose leaders have…
There is no doubting the importance of the Brexit trade deal, given how closely linked the EU and the UK markets are. There are enormous numbers involved; every month at least…